GoKawiilProposal: price AI research breakthroughs separately from startup equity
A commentary piece argues that AI 'neolabs'—new research-focused startups founded by senior researchers—are currently forced to pursue both a scientific breakthrough and a venture-scale business simultaneously, which it says compounds already low odds. The author proposes a model borrowed from pharmaceutical R&D that would let frontier labs, neolabs, and investors separate and price these risks differently.